| Literature DB >> 35800289 |
Jiandong Lu1, Lin Wang1, Yi Wei1, Shengde Wu1, Guanghui Wei1.
Abstract
Background: To investigate the etiological characteristics and risk factors of extended-spectrum beta-lactamase (ESBL) urinary tract infection (UTI) and construct a corresponding nomogram to predict the probability of ESBL(+) UTI.Entities:
Keywords: Urinary tract infection (UTI); extended-spectrum beta-lactamase producing bacteria (ESBL-producing bacteria); neurological disorder; risk factor; urological abnormalities
Year: 2022 PMID: 35800289 PMCID: PMC9253944 DOI: 10.21037/tp-21-523
Source DB: PubMed Journal: Transl Pediatr ISSN: 2224-4336
Figure 1Trend of antibiotics resistance in UTI between 1994 and 2019. We assessed the changing trends of ESBL-producing pathogens in E. coli and K. pneumoniae, which are the most common in UTI. (A) Among the whole isolated bacteria in UTIs, the proportion of ESBL-producing pathogens increased significantly (P=0.003); (B) among E. coli UTI, there was an observed increase in the proportion of ESBL producing pathogens (P=0.021); (C) among the UTIs exhibiting a microbial etiology attributed to K. pneumoniae, the proportion of ESBL-producing pathogens did not increase (P=0.482). UTI, urinary tract infection; EBSL, extended-spectrum-β-lactamase.
Figure 2Susceptibility and resistance trends of commonly-prescribed antibiotics for ESBL-UTI. The overall susceptibility and trend of susceptibility to commonly-prescribed antibiotics were reviewed. The overall susceptibility was relatively high to vancomycin (100.00%), carbapenems (90.10%), amikacin (91.90%) and relatively low to the 2nd generation cephalosporins (11.22%), the 3rd generation cephalosporins (15.18%) and amoxicillin/clavulanic acid (21.86%). UTI, urinary tract infection; EBSL, extended-spectrum-β-lactamase.
Risk factors for acquisition of ESBL producing UTI (n=519)
| Risk factors | ESBL (−), n (%) | ESBL (+), n (%) | χ2 | P value |
|---|---|---|---|---|
| Total (n=519) | 142 | 377 | ||
| Patients with congenital urological malformations (n=381) | 89 | 292 | 9.79 | 0.002* |
| Patients with no urological malformations (n=138) | 52 | 86 | ||
| Patients with vesicoureteral reflux (n=102) | 19 | 83 | 4.158 | 0.041* |
| Patients with no vesicoureteral reflux (n=417) | 122 | 295 | ||
| Patients with urodynamic change (n=38) | 10 | 28 | 0.000 | 1.000 |
| Patients with no urodynamic change (n=481) | 131 | 350 | ||
| Patients with neurologic disorder (n=32) | 2 | 30 | 6.457 | 0.011* |
| Patients with no neurologic disorder (n=487) | 139 | 348 | ||
| Patients with undernourishment | 2 | 12 | 1.969 | 0.425 |
| Patients with no undernourishment | 140 | 365 | ||
| Age <12 months (n=241) | 49 | 192 | 9.99 | 0.002* |
| Age ≥12 months (n=278) | 92 | 186 | ||
| Side of the lesion: bilateral (n=252) | 69 | 183 | 0.049 | 0.976 |
| Side of the lesion: left (n=162) | 43 | 119 | ||
| Side of the lesion: right (n=105) | 29 | 76 | ||
| Male (n=334) | 84 | 250 | 1.653 | 0.199 |
| Female (n=185) | 57 | 128 | ||
| Fever (n=75) | 10 | 65 | 7.682 | 0.006* |
| No fever (n=444) | 131 | 313 | ||
| Previous UTI in the last 3 months (n=241) | 39 | 202 | 26.412 | 0.000* |
| No UTI in the last 3 months (n=278) | 102 | 176 | ||
| Previous antibiotics administration in the last 3 months (n=285) | 41 | 244 | 50.768 | 0.000* |
| No antibiotics administration in the last 3 months (n=234) | 100 | 134 |
*, P<0.05. EBSL, extended-spectrum-β-lactamase; UTI, urinary tract infection.
Logistic regression analysis of risk factors for acquisition of ESBL producing UTI
| Variable | OR (95% CI) | P value |
|---|---|---|
| Presence of underlying neurologic disorder | ||
| No | 1 | |
| Yes | 8 (1.845–34.695) | <0.01 |
| Previous antibiotics administration in the last 3 months | ||
| No | 1 | |
| Yes | 4.764 (3.114–7.289) | <0.01 |
95% CI, 95% confidence interval; OR, odds ratio; EBSL, extended-spectrum-β-lactamase; UTI, urinary tract infection.
Figure 3Nomogram to predict ESBL (+) UTI (A) and calibration plot for predicting ESBL (+) UTI (B). EBSL, extended-spectrum-β-lactamase; UTI, urinary tract infection.